Small molecule FLT3 tyrosine kinase inhibitors

Research output: Contribution to journalReview articlepeer-review

Abstract

Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

Original languageEnglish (US)
Pages (from-to)1183-1193
Number of pages11
JournalCurrent pharmaceutical design
Volume10
Issue number11
DOIs
StatePublished - 2004

Keywords

  • AML
  • FLT3
  • Kinase inhibitor
  • Tyrosine kinase

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Small molecule FLT3 tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this